Daewoong Pharmaceutical Balance Sheet Health
Financial Health criteria checks 3/6
Daewoong Pharmaceutical has a total shareholder equity of ₩951.4B and total debt of ₩614.9B, which brings its debt-to-equity ratio to 64.6%. Its total assets and total liabilities are ₩1,922.5B and ₩971.1B respectively. Daewoong Pharmaceutical's EBIT is ₩136.5B making its interest coverage ratio 34.5. It has cash and short-term investments of ₩107.5B.
Key information
64.6%
Debt to equity ratio
₩614.89b
Debt
| Interest coverage ratio | 34.5x |
| Cash | ₩107.51b |
| Equity | ₩951.35b |
| Total liabilities | ₩971.10b |
| Total assets | ₩1.92t |
Recent financial health updates
Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15
We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Recent updates
Impressive Earnings May Not Tell The Whole Story For Daewoong Pharmaceutical (KRX:069620)
Nov 22There's Reason For Concern Over Daewoong Pharmaceutical Co., Ltd's (KRX:069620) Price
Nov 06Daewoong Pharmaceutical (KRX:069620) Seems To Use Debt Quite Sensibly
Oct 15Daewoong Pharmaceutical Co., Ltd (KRX:069620) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 13Daewoong Pharmaceutical Co., Ltd's (KRX:069620) 27% Price Boost Is Out Of Tune With Earnings
Jul 24We Think Daewoong Pharmaceutical (KRX:069620) Can Stay On Top Of Its Debt
Jul 04Financial Position Analysis
Short Term Liabilities: A069620's short term assets (₩574.2B) exceed its short term liabilities (₩538.1B).
Long Term Liabilities: A069620's short term assets (₩574.2B) exceed its long term liabilities (₩433.0B).
Debt to Equity History and Analysis
Debt Level: A069620's net debt to equity ratio (53.3%) is considered high.
Reducing Debt: A069620's debt to equity ratio has increased from 61.7% to 64.6% over the past 5 years.
Debt Coverage: A069620's debt is not well covered by operating cash flow (6.9%).
Interest Coverage: A069620's interest payments on its debt are well covered by EBIT (34.5x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 08:06 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Daewoong Pharmaceutical Co., Ltd is covered by 27 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Hyonseok Kim | CLSA |
| Heeyoung Lee | Daishin Securities Co. Ltd. |